-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Beijing Kangchen Pharmaceutical Co.
, Ltd.
(hereinafter referred to as the "Company") recently announced the phase II clinical trial information
of KC1036 for the treatment of advanced thymic tumor patients on the drug clinical trial registration and information disclosure platform of the State Medical Products Administration.
This phase II clinical study has passed the review of the Clinical Trial Ethics Review Committee of West China Hospital of Sichuan University and the Ethics Committee of Shanghai Chest Hospital, and will officially start the recruitment of
subjects in the near future.
KC1036 tablets (hereinafter referred to as "KC1036") is a Class 1 innovative chemical drug independently developed by the company that is not on the market at home and abroad, and is intended for the treatment
of solid tumors.